Segment and Geographic Information (Notes)

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Reporting Segments

Segment and Geographic Information

The structure of the Company’s internal organization is divided into the following reportable segments, which are also the Company’s operating segments: E&C, D&S and BioMedical. The Company’s reportable segments are business units that are each managed separately because they manufacture, offer and distribute distinct products with different production processes and sales and marketing approaches. The E&C and D&S segments manufacture products used primarily in energy-related and industrial applications, such as the separation, liquefaction, distribution and storage of hydrocarbon and industrial gases. The BioMedical segment supplies cryogenic and other equipment used in the medical, biological research and animal breeding industries. Due to the nature of the products that each segment sells, intersegment sales are not material. Corporate includes operating expenses for executive management, accounting, tax, treasury, corporate development, human resources, information technology, investor relations, legal, internal audit, risk management and share-based compensation expenses that are not allocated to the reporting segments.

The Company evaluates performance and allocates resources based on operating income or loss from continuing operations before interest expense, net, financing costs amortization, foreign currency loss (gain), income tax expense, net and noncontrolling interests, net of taxes. The accounting policies of the reportable segments are the same as those described in Note 2.

Segment Financial Information

	Year Ended December 31, 2015
	Energy & Chemicals			Distribution & Storage		BioMedical			Corporate			Total
Sales to external customers	$	330,968		$	487,557	$	221,635		$	—		$	1,040,160
Depreciation and amortization expense	11,805			18,289		12,039			3,315			45,448
Operating (loss) income (1)	(8,138		)	41,732		(164,284		)	(52,533		)	(183,223		)
Total assets (2)	251,810			689,112		224,443			36,611			1,201,976
Capital expenditures	4,074			36,835		3,849			2,281			47,039

	Year Ended December 31, 2014
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales to external customers	$	388,018	$	578,806	$	226,128	$	—		$	1,192,952
Depreciation and amortization expense	9,649		16,749		13,842		2,936			43,176
Operating income (loss) (3)	79,665		85,213		25,694		(52,415		)	138,157
Total assets (2)	322,936		666,451		396,320		76,356			1,462,063
Capital expenditures	24,834		29,583		3,484		4,234			62,135

	Year Ended December 31, 2013
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales to external customers	$	318,510	$	592,616	$	266,312	$	—		$	1,177,438
Depreciation and amortization expense	8,564		15,237		14,618		1,970			40,389
Operating income (loss)	59,671		93,560		33,039		(50,273		)	135,997
Total assets (2)	277,760		676,484		431,763		75,623			1,461,630
Capital expenditures	34,194		32,039		3,370		2,982			72,585

_______________

⁽¹⁾  Includes asset impairment charges of $255,116 for the year ended December 31, 2015, attributed to E&C - $68,796, D&S - $2,020 , and BioMedical - $184,300.

⁽²⁾  Corporate assets consist primarily of cash, cash equivalents and deferred income taxes.

⁽³⁾  The BioMedical segment’s operating income included recovery of $5,003 increasing operating income for the year ended December 31, 2014 from an escrow settlement for breaches of representations and warranties relating to warranty costs (which are in excess of the settlement amount) for certain product lines acquired from AirSep in 2012.

The following table represents the changes in goodwill by segment:

	Energy & Chemicals			Distribution & Storage			BioMedical			Total
Balance at January 1, 2014	$	83,215		$	160,054		$	155,636		$	398,905
Foreign currency translation adjustments and other	130			(2,806		)	—			(2,676		)
Goodwill acquired during the year	9,293			—			—			9,293
Balance at December 31, 2014	92,638			157,248			155,636			405,522
Foreign currency translation adjustments and other	(162		)	(1,909		)	184			(1,887		)
Goodwill acquired during the year	—			10,601			—			10,601
Impairment loss	(64,603		)	—			(131,243		)	(195,846		)
Balance at December 31, 2015	$	27,873		$	165,940		$	24,577		$	218,390
Accumulated goodwill impairment loss	$	64,603		$	—		$	131,243		$	195,846

Product Sales Information

	Year Ended December 31,
	2015		2014		2013
Energy & Chemicals
Natural gas processing (including petrochemical) applications	$	180,909	$	208,706	$	175,397
Liquefied natural gas applications	136,049		143,870		114,567
Industrial gas applications	14,010		35,442		28,546
Total Energy & Chemicals	330,968		388,018		318,510
Distribution & Storage
Bulk industrial gas applications	203,834		204,214		241,291
Packaged gas industrial applications	167,814		164,966		158,293
Liquefied natural gas applications	115,909		209,626		193,032
Total Distribution & Storage	487,557		578,806		592,616
BioMedical
Respiratory therapy	132,321		141,273		175,233
Life sciences	64,641		65,948		61,493
Commercial oxygen generation	24,673		18,907		29,586
Total BioMedical	221,635		226,128		266,312
Total	$	1,040,160	$	1,192,952	$	1,177,438

Geographic Information

Net sales by geographic area are reported by the destination of sales. Net property, plant and equipment by geographic area are reported by country of domicile.

	Sales for the Year Ended December 31,
	2015		2014		2013
United States	$	513,691	$	560,846	$	479,067
Foreign
China	109,978		188,047		231,143
Other foreign countries	416,491		444,059		467,228
Total Foreign	$	526,469	$	632,106	$	698,371
Total	$	1,040,160	$	1,192,952	$	1,177,438

	Property, plant and equipment, net as of December 31,
	2015		2014		2013
United States	$	153,987	$	163,425	$	146,610
Foreign
Czech Republic	19,742		22,511		23,623
China	79,691		57,580		38,569
Germany	12,246		13,495		14,618
Other foreign countries	611		634		785
Total Foreign	$	112,290	$	94,220	$	77,595
Total	$	266,277	$	257,645	$	224,205